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Abstract
Background: Legionella pneumophila is an important causative agent of severe pneumonia in humans. Human 
alveolar epithelium and macrophages are effective barriers for inhaled microorganisms and actively participate in the 
initiation of innate host defense. The beta defensin-3 (hBD-3), an antimicrobial peptide is an important component of 
the innate immune response of the human lung. Therefore we hypothesize that hBD-3 might be important for 
immune defense towards L. pneumophila.
Methods: We investigated the effects of L. pneumophila and different TLR agonists on pulmonary cells in regard to 
hBD-3 expression by ELISA. Furthermore, siRNA-mediated inhibition of TLRs as well as chemical inhibition of potential 
downstream signaling molecules was used for functional analysis.
Results: L. pneumophila induced release of hBD-3 in pulmonary epithelium and alveolar macrophages. A similar 
response was observed when epithelial cells were treated with different TLR agonists. Inhibition of TLR2, TLR5, and 
TLR9 expression led to a decreased hBD-3 expression. Furthermore expression of hBD-3 was mediated through a JNK 
dependent activation of AP-1 (c-Jun) but appeared to be independent of NF-κB. Additionally, we demonstrate that 
hBD-3 elicited a strong antimicrobial effect on L. pneumophila replication.
Conclusions: Taken together, human pulmonary cells produce hBD-3 upon L. pneumophila infection via a TLR-JNK-AP-
1-dependent pathway which may contribute to an efficient innate immune defense.
Background
Legionella pneumophila is the causative agent of Legion-
naires' disease, a severe pneumonia with high mortality
[1]. The bacterium enters the human body by aerosol
droplets and successfully establishes itself in mac-
rophages and the alveolar epithelium, which normally
offer an efficient barrier against infections [2]. Among the
various putative virulence factors of this pathogen that
have been identified to date, the type II (Lsp) and IVB
(Dot/Icm) secretion system enable the bacteria to export
proteins and therefore activates diverse cell signaling
pathways [3,4]. Furthermore, bacterial cytoplasm mem-
brane components, flagellin, and bacterial DNA, all
major pathogen-associated factors of L. pneumophila,
which activate innate immune response of alveolar epi-
thelium as well as in macrophages [5-7]. L. pneumophila
can be detected by means of toll-like receptors (TLR) or
cytosolic pathogen pattern recognition receptors. Indeed
it has been demonstrated that the atypical Legionella LPS
can be recognized by TLR2, flagellin through TLR5 and
DNA via TLR9 [5-7]. To clear L. pneumophila from the
lung, a functionally intact innate immune system must be
present. There is increasing evidence that human β-
defensins (hBDs), a family of endogenous, cationic anti-
microbial and immunomodulatory peptides secreted at
epithelial mucosal and macrophages are critical compo-
nents of host defense [8,9]). The human β-defensin (hBD)
family comprises multiple members. While hBD-1 is con-
stitutively expressed [9], production of hBD-2 and hBD-3,
can be induced upon stimulation with bacteria and/or
cytokines [10-12]. hBD-3 is, unlike other hBDs, a salt-
insensitive defensin with a broad antimicrobial activity
against e.g. multidrug-resistant nosocomial strains [10-
13]. It has been reported that hBD-3 is expressed by pul-
monary epithelial cells and increases in respiratory tract
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and serum of patients with bacterial pneumonia [14].
Consequently, the antibacterial properties of hBD-3 have
attracted the attention of researchers in the field of pul-
monary diseases.
Expression of hBD-3 is controlled by a tight regulatory
network involving the transcription-factors Nuclear Fac-
tor-κB (NF-κB) and the Activator Protein-1 (AP-1) [15-
17]. These transcription factors are activated by complex
signalling pathways, including the JNK mitogen-activated
protein kinase (MAPK) [18]. Although L. pneumophila
efficiently infects and activates lung epithelial cells and
alveolar macrophages [19-21], and hBD-3 secretion was
observed in patients with bacterial pneumonia [14], regu-
latory mechanisms of hBD-3 production in L. pneumo-
phila infections is widely unknown.
In the study presented, we demonstrate that L. pneu-
mophila induced hBD-3 in alveolar epithelium and mac-
rophages. The hBD-3 expression was controlled by TLR2,
TLR5 and TLR9, as well as activation of JNK and AP-1 (c-
Jun) whereas NF-κB was not required. Also, recombinant
hBD-3 elicited a strong antimicrobial effect on L. pneu-
mophila. Moreover, inhibition of hBD-3 expression
increased the L. pneumophila intracellular growth in pul-
monary epithelium. Thus, hBD-3 production by pulmo-
nary cells may contribute to the host response in
Legionnaires' disease. Our results may significantly con-
tribute to the understanding of the pathogenesis of
Legionnaires' disease.
Materials and methods
Materials
Recombinant human BD-3 was purchased from cell-
sciences (Canton, MA, USA). Erythromycin, Malp-2
(TLR2 ligand), ODN M362 (TLR9 ligand, a non-methy-
lated CpG motif), and flagellin (TLR5 ligand) from Sal-
monella enterica serovar typhimurium were all
purchased from Sigma Chem. Co. (Munich, Germany).
TNFα were purchased from R&D Systems (Wiesbaden,
Germany). The JNK inhibitor (JNK II), the NF-κB inhibi-
tor (NF-κB activator inhibitor) and MG-132 were all pur-
chased from Calbiochem (Darmstadt, Germany). All
other chemicals used were of analytical grade and
obtained from commercial sources.
Cell lines
Alveolar macrophages
Human alveolar macrophages were obtained by broncho-
alveolar lavages (BAL) of patients from routine diagnos-
tic. The study was approved by the local ethics committee
of the Charité-Universitätsmedizin Berlin in accordance
with the ethical rules stated in the Declaration of Hel-
sinki. Cells were recovered, washed twice in cold PBS,
then resuspended at 106/ml in RPMI 1640 (PAA, Pasch-
ing, Austria) with 10% heat-inactivated FCS and antibiot-
ics. Alveolar macrophages were placed into 24-well tissue
culture plates and allowed to adhere for 2 h. The mono-
layers were then washed three times to remove non-
adherent cells and antibiotics, and cultured in RPMI 1640
with 10% heat-inactivated FCS until infections.
Airway epithelial cells
Primary human small airway epithelial cells (SAEC) were
obtained from Cambrex (Cambrex, Taufkirchen, Ger-
many) and cultured according to the supplier's instruc-
tions. The alveolar epithelial cell line A549 was purchased
from DSMZ (Braunschweig, Germany) and cultured in
HAM'S F 12 (PAA, Pasching, Austria) with L-glutamine,
10% FCS without antibiotics.
Infection with bacterial strains
L. pneumophila sg1 strain 130b (ATCC BAA-74, kindly
provided by N. P. Cianciotto, Chicago, USA), strain JR32
(wild type), JR32ΔdotA deficient in dot/icm, encoding a
protein essential for the type IVB secretion system
(kindly provided by H. Shuman, New York, USA), strain
Corby (wild type), CorbyΔflaA deficient in flagellin as
well as its type II secretion system knock out Cor-
byΔlspDE [3] were routinely grown on buffered charcoal-
yeast extract (BCYE) agar for 2 days at 37°C before used
[22]. Heat inactivation of L. pneumophila was accom-
plished in a water bath at 56°C for 30 min. No live bacte-
ria were detected after this suspension was plated onto
agar plates. The used cells were infected with L. pneumo-
phila with a multiplicity of infection (MOI) of 10 at 37°C
and 5% CO2.
Replication assay
To address the antimicrobial activity of hBD-3 towards L.
pneumophila, 105  cfu/ml bacteria were suspended in
HAM's 12 without supplements and recombinant hBD-3
was added. Bacteria growth was enumerated by plating
suspension on agar plates as colony-forming-units (cfu).
For the intracellular replication assay, A549 cells were
infected with L. pneumophila 130b. After 2 h, cells were
washed with PBS and remaining extracellular bacteria
were killed by the cell-impermeable antibiotic gentamy-
cin (50 μg/ml, Invitrogen, Karlsruhe, Germany) for 1 h.
Afterwards cells were washed twice with PBS (time point
0) and incubated in HAM's 12 medium without supple-
ments with recombinant hBD-3. Intracellular bacteria
were enumerated by lysed cell suspension plated on agar
plates as cfu.
Isolation of bacterial DNA
Bacterial DNA from Legionella was prepared using a Qia-
gen construct kit protocol for endotoxin-free isolation of
bacterial DNA (Qiagen, Hilden, Germany) as described
elsewhere [23].
RNA interference in A549 cells
A549 cells were transfected by using Amaxa Nucleofec-
tor™ (Amaxa, Köln, Germany) according to the manufac-
turer's protocol (Nucleofector™ Solution V, Nucleofector™Scharf et al. Respiratory Research 2010, 11:93
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program G-16) with 2 μg siRNA per 106 cells. Control
non-silencing siRNA (sense UUCUCCGAACGUGU-
CACGUtt, antisense ACGUGACACGUUCGGAGAA),
siRNA targeting TLR2 (sense GCACUUUAUAUUCAC-
UUACtt, antisense GUAAGUGAAUAUAAAGUGCtc),
TLR5 (sense GGAGCAAUUUCCAACUUAUtt, anti-
sense AUAAGUUGGAAAUUGCUCCtt), and siRNA
targeting TLR9 (sense CUGUCCUUCAAUUACCAAAtt
antisense GUAAUUGAAGGACAGgt) were purchased
from MWG (Ebersberg, Germany).
Polymerase chain reaction (RT-PCR)
Total RNA from cells was isolated with the RNeasy Mini
kit (Qiagen, Hilden, Germany) and was reverse-tran-
scribed using M-MLV reverse transcriptase (Invitrogen,
Karlsruhe, Germany). The generated cDNA was ampli-
fied by semi-quantitative RT-PCR using RedTaq poly-
merase (Qiagen, Hilden, Germany). Primers specific for
GAPDH (encoding glyceraldehydes phosphate dehydro-
genase; 5-CCACCCATGGCAAATTCCATGGCA-3' and
5-TCTAGACGGGCAGGTCAGGTCCACC-3') and
hBD-3 (5-TCTCAGCGTGGGGTGAAGC-3' and 5'-
CGGCCGCCTCTGACTCTG-3') were used. Primers
were from TIB Molbiol (Berlin, Germany). After amplifi-
cation, PCR products were separated by electrophoresis
through a 2% agarose gels, stained with ethidium bro-
mide and then visualized. GAPDH expression was used
to confirm use of equal amounts of cDNA in each experi-
ment.
hBD-3 ELISA
A549, SAEC and alveolar macrophages were infected as
indicate, supernatants were collected. Samples were 10
times concentrated with Amicon Ultra-15 Centrifugal
Filter Unit with Ultracel-3 membrane according to manu-
facturer instructions (Millipore GmbH, Schwalbach, Ger-
many) and processed for hBD-3 quantification by ELISA
(Phoenix Pharmaceuticals Inc., Belmont, CA, USA).
Since the probes were 10 times concentrated, we pre-
sented in the figures the concentration of hBD-3 corre-
sponding to a non concentrated probe.
Western Blot
A549 cells were transfected or infected as indicated. Cells
were lysed in buffer containing Triton X-100, subjected to
SDS-PAGE and blotted on Hybond-ECL membrane
(Amersham Biosciences, Freiburg, Germany). Immuno-
detection of target proteins was carried out with specific
antibodies against p-JNK, JNK, c-Jun, β-actin (antibodies
were purchased from Santa Cruz Biotechnologies, Santa
Cruz, CA, USA) and p-c-Jun (Ser 73) (purchased from
Cell Signaling, Frankfurt, Germany). In all experiments,
β-actin was detected simultaneously to confirm equal
protein load.
Chromatin immunoprecipitation
A549 cells were infected with L. pneumophila 130b. Cells
were processed for chromatin immunoprecipitation
(ChIP) as described elsewhere [21]. hbd-3 promoter DNA
was amplified by PCR using RedTaq polymerase (Qiagen,
Hilden, Germany). PCR products were separated by aga-
rose gel electrophoresis and detected by ethidium bro-
mide staining of gels. Equal amounts of input DNA were
confirmed by gel electrophoresis. For immunoprecipita-
tion, the antibodies used were purchased from Santa
Cruz Biotechnology (polymerase II, c-Jun), Frankfurt,
Germany. The following promoter-specific primers for
hbd3  were used: sense 5'-TCCCAGAACTAACACAC-
CCTT-3' and antisense 5'-TTCCAGCCACAGCTG-
CAATT-3'.
Statistical methods
Data are shown as means ± SEM of at least three inde-
pendent experiments. A one-way ANOVA test was used
for data of figure 1D - F; Figure 2; Figure 3A and B; Figure
4A and 4C. The main effects were then compared by a
Newman-Keuls' post-test. A two way ANOVA test was
used for data of Figure 3C, D and 3E and Figure 5 and
main effects were compared by a Bonferroni post-test. P
< 0.05 was considered to be significant and indicated by
asterisks or H-Keys. If not indicated otherwise, test was
performed vs. control (*) or stimulated probe vs. inhibitor
treated probe (#).
Results
L. pneumophila induced hBD-3 expression of human 
alveolar epithelial cells and macrophages
SAEC, A549 cells as well as primary human alveolar mac-
rophages were infected with L. pneumophila strain 130b
or stimulated with TNFα as control for different periods
of time and analyzed by RT-PCR and ELISA (Figure 1).
An increased mRNA level of hBD-3 was observed in pri-
mary lung cells (SAEC) (figure 1A), in A549 cells (figure
1B) and in primary alveolar macrophages (figure 1C).
Furthermore, a strong hBD-3 release could be demon-
strated by ELISA in all three cell types infected with L.
pneumophila (figure 3D - F). This suggests an important
role of hBD-3 for the L. pneumophila-induced innate
immune response of the lung. In A549, a time dependent
increase of hBD-3 release (figure 1E) was observed. Next
we addressed the mechanisms involved in L. pneumo-
phila- induced hBD-3 expression by using A549 cells.
The type II and IV secretion systems of L. pneumophila are 
not essential for hBD-3 release of alveolar epithelial cells
The type II (lsp) as well as the Dot/Icm type IVB secre-
tion system is known to be important pathogen factors of
L. pneumophila [3,4]. Infection of A549 cells with L.
pneumophila strains JR32 and Corby induced comparable
hBD-3 release to strain 130b (figure 1B, 2) suggesting that
induction of this peptide is common in L. pneumophila
infection of alveolar epithelium. Furthermore, no signifi-Scharf et al. Respiratory Research 2010, 11:93
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cant differences could be observed among the effects of
JR32ΔdotA (figure 2) and CorbyΔlspDE (figure 2) dele-
tion mutants and wild-type strains with respect to hBD-3
liberation. These data suggest that the types II as well as
the type IVB secretion system and their effector mole-
cules are not involved in L. pneumophila-induced hBD-3
release. Furthermore, data indicates that intracellular
replication of L. pneumophila appears not to be required
for L. pneumophila- induced release of hBD-3, because
the presence of the type IVB secretion system was shown
not to be important.
hBD-3 release induced by L. pneumophila in alveolar 
epithelial cells is controlled by TLR2, TLR5 , and TLR9
Following our previous and present observations that L.
pneumophila  strongly activates lung epithelial cells
[20,21,24], we tested the hypothesis that TLR2, TLR5,
and TLR9 might be essential for the observed hBD-3
induction. To address this issue we stimulated SAEC with
the TLR2 ligand Malp-2, the TLR5 ligand flagellin and
non-methylated CpG-motifs (ODN) as ligand for TLR9.
Incubation of SAEC with all agonists stimulated the
release of hBD-3 (figure 3A). Furthermore we assessed
the role of flagellin for the L. pneumophila induced hBD-
Figure 1 L. pneumophila mediates hBD-3 release. (A, D) SAE cells, (B, E) A549 cells and (C, F) alveolar macrophages (aMϕ) were infected with L. pneu-
mophila 130b (L. p.) for indicated time points (A-C) or for 24 h (D-F) as well as (E) incubated with TNFα [100 ng/ml] for 24 h. RT-PCR with specific hBD-
3 primer was performed (A-C) and hBD-3 release was measured by ELISA (D-F). Representative gels out of three independent experiments are shown. 
ELISA results are means ± SEM of three independent experiments. *, p < 0.05 compared with uninfected control cells.
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Figure 2 The type II and IVB secretion systems of L. pneumophila are not essential for hBD-3 release in A549 cells. A549 cells were infected 
with (A) L. pneumophila JR32, JR32ΔdotA, and (B) Corby as well as CorbyΔlspDE for 24 h. hBD-3 release was analyzed by ELISA. ELISA data presented 
are means ± SEM of four separate experiments. *, p < 0.05 compared with uninfected control cells.
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Figure 3 hBD-3 release induced by L. pneumophila in alveolar epithelial cells is controlled by TLR2, TLR5 and TLR9. (A) SAEC were incubated 
with the TLR2 ligand Mapl 2 [1 μg/ml], purified flagellin to activte TLR5 [1 μg/ml] and ODN as TLR9 ligand [1 μM]. After 24 h hBD-3 release was measure 
by ELISA. RNAi experiments in A549 cells to inhibit expression of endogenous TLR2, TLR5 or TLR9 respectively were performed. Cells were incubated 
for 72 h with TLR2- and for 48 h with TLR5- and TLR9-specific siRNA as well as a non-silencing control siRNA (C-siRNA). Infection with L. pneumophila 
strain 130b (L. p.), incubation with TNFα [100 ng/ml] or (B) the TLR2 ligand Malp 2 [1 μg/ml] and heat inactivated L. pneumophila, Corby, CorbyΔflaA 
or (C, D) incubated with flagellin [1 μg/ml] and (E) the TLR9 ligand ODN [1 μM] and DNA [5 μg/ml] from Legionella. After 24 h hBD-3 release was mea-
sure by ELISA. ELISA data presented are means ± SEM of four separate experiments. *, p < 0.05 compared with uninfected control cells; #, p < 0.05 
control siRNA versus target siRNA.
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3 release in detail by infecting A549 cells with wild type
Legionella as well as a flagellin-deficient mutant strain
(CorbyΔflaA) (figure 3B). When comparing the wild type
strain with a flagellin-deficient mutant (CorbyΔflaA) sig-
nificant difference in hBD-3 release could be observed
(figure 3B), indicating that activation of TLR5 was impor-
tant for hBD-3 secretion in L. pneumophila infected cells.
To further examine the role of the TLRs we performed
RNAi experiments in A549 cells to inhibit expression of
endogenous TLR2, TLR5, and TLR9, respectively. We
first confirmed that the TLR2-, TLR5- or TLR9-specific
siRNA constructs but not the control siRNA resulted in
the repression of protein levels in A549 cells (data not
shown). A549 cells were transfected with TLR2-specific
siRNA or control siRNA and were incubated with heat
inactivated L. pneumophila, Malp-2 or infected with L.
pneumophila 130b (figure 3C). Heat inactivated L. pneu-
mophila induced hBD-3 release to the same extend as the
viable L. pneumophila bacteria. Activation of TLR2 (with
Malp-2) led to a similar hBD-3 release in A459 cells
transfected with control siRNA. Reduced hBD-3 libera-
tion could be observed in cells transfected with TLR2-
specific siRNA (figure 3C). Next we infected TLR5-spe-
cific siRNA-transfected A549 cells with L. pneumophila
or incubated cells with flagellin and observed a decreased
hBD-3 release mediated by depletion of TLR5 (figure
3D). Furthermore we addressed the role of TLR9 sensing
nucleic acids in this process. Therefore A549 cells were
transfected with specific TLR9-siRNA and afterwards
incubated with purified L. pneumophila-DNA and ODN
or infected with L. pneumophila (figure 3E). L. pneumo-
phila-DNA and ODN strongly induced hBD-3 release to
the same extent as the wild type strain and liberation of
this peptide was reduced in all cells transfected with spe-
cific-TLR9-siRNA. In all RNAi experiments TNFα-
related hBD-3 production (figure 3) was not reduced.
Overall, our observations suggest an important role for
TLR2, TLR5 and TLR9 with respect to the hBD-3 induc-
tion observed in alveolar epithelium.
hBD-3 expression in L. pneumophila - infected cells requires 
AP-1 (c-Jun)
Recent studies showed that activation of NF-κB and/or
AP-1 (c-Jun) controls hBD-3 expression [15-19]. There-
fore, to further investigate a possible role of NF-κB acti-
vation for L. pneumophila-dependent hBD-3 release, we
pre-incubated A549 cells with the proteasome inhibitor
MG-132 to prevent IκB degradation. In addition we made
Figure 4 hBD-3 expression in L. pneumophila - infected cells requires AP-1 (c-Jun). (A) A549 cells were pre-incubated with the proteasome in-
hibitor MG-132 [10 μM] or the NF-κB activation inhibitor [10 μM] for 1 h before infected with L. pneumophila 130b for 24 h. Induction of hBD-3 release 
was measured by ELISA. (B) To elucidate the contribution of the JNK-AP-1 pathway, L. pneumophila mediated activation of JNK was detected time de-
pendent by western blot analysis and (C) A549 cells were pre-incubated with the JNK inhibitor JNK II [10 μM] for 1 h before infected with L. pneumo-
phila 130b for 24 h. Induction of hBD-3 release was measured by ELISA. (D) c-Jun phosphorylation was assessed by western blotting after infection of 
A549 cells with L. pneumophila 130b at indicated time points. (E) Furthermore A549 cells were infected with L. pneumophila 130b at indicated time 
points and the binding patterns of Polymerase II (Pol II), and c-Jun to the hBD-3 promoter were analyzed by ChIP. Representative gels or blots out of 
three independent experiments are shown. ELISA data presented are means ± SEM of three separate experiments. *, p < 0.05 compared with unin-
fected control cells; #, p < 0.05 infected cells versus infected cells with specific inhibitors.
- 0.5    1     2     4   [h]   
L. p.
JNK
p-JNK
L. p.
MG-132
NF-B activation
inhibitor
** ** **
h
B
D
-
3
 
[
p
g
/
m
l
]
100
200
-
-
-
-
-
-
--
-
- ++
++
+
-
+
+
L. p.
JNK II
#
-
--
- ++
++
**
h
B
D
-
3
 
[
p
g
/
m
l
]
100
200
c-Jun
p-c-JunSer73
- 0.5    1     2     4   [h]   
L. p.
Input
Pol II 
c-Jun
- 0.5    1     2     4  [h]
L. p.
D
A B C
EScharf et al. Respiratory Research 2010, 11:93
http://respiratory-research.com/content/11/1/93
Page 8 of 12
use of a NF-κB activity inhibiting peptide. Blocking IκB
degradation by MG-132 or inhibiting NF-κB activity did
not have any effect on hBD-3 release (figure 4A) in L.
pneumophila-infected A549 cells whereas interleukin-8
release was significantly reduced (data not shown). Our
data demonstrated that activation of NF-κB by L. pneu-
mophila was not important for hBD-3 release in lung epi-
thelium.
Activation of JNK is considered to participate in the
regulation of inflammatory processes in alveolar epithe-
lial cells [25]. Phosphorylation of the JNK kinase by L.
pneumophila infection of epithelial cells was detected 1 h
after infection, increased up to 2 h, and decreased slightly
at 4 h (figure 4B). Since JNK-mediated phosphorylation
enhances the ability of c-Jun, a component of the AP-1
transcription factor, to activate transcription [20], we
inhibited this kinase by pre-incubation of A549 cells with
a JNK inhibitor (JNK II) before infection with L. pneumo-
phila  130b. As shown in figure 4C, inhibition of JNK
abolished L. pneumophila induced hBD-3 release. These
observations suggest that JNK is important for the L.
pneumophila-induced hBD-3 release in lung epithelial
cells.
To further investigate the role of AP-1, we addressed
the AP-1 subunit c-Jun activation following infection of
alveolar epithelial cells with L. pneumophila. We
observed a time dependently increased phosphorylation
at serine 73 of the AP-1 subunit c-Jun (figure 4D).
To characterize the mechanism by which AP-1 (c-Jun)
contributes to L. pneumophila-induced hBD-3 expres-
sion, the recruitment of c-Jun to the hbd-3 promoter were
evaluated by ChIP assay. We observed an increase of the
AP-1 subunit c-Jun binding to the hbd-3 promoter (figure
4E) whereas the NF-κB subunit p65 was not recruited
(data not shown). An increased binding of the RNA poly-
merase II (Pol II) to the hbd-3 promoter was indicative
for the subsequent activation of the hbd-3  gene in
infected A549 cells. These experiments confirm that the
JNK-AP-1 (c-Jun) pathway controls hBD-3 expression in
L. pneumophila infected alveolar epithelial cells.
The chemical inhibitors used in these experiments did
neither reduce viability and proliferation of the A549 cells
nor induces morphological signs of cytotoxicity, or altera-
tions of bacterial growth within the time-frame tested
(data not shown).
Figure 5 hBD-3 elicited a strong antimicrobial effect on L. pneumophila. (A) L. pneumophila 130b (L. p.) was incubated at 105 cfu/ml in HAM's 12 
with increasing concentrations of recombinant hBD-3 (rhBD-3) and erythromycin [erythr.; 0.5 μg/ml] as indicated and multiplication of bacteria was 
assessed by colony forming units (cfu) assay plating solution mixture on agar plates after 4 and 8 h. (B) A549 epithelial cells were infected with L. pneu-
mophila 130b and replication assay was performed. (C) A549 epithelial cells were transfected with control siRNA (c-siRNA) or specific siRNA targeting 
hBD-3, and after 48 h infected with L. pneumophila 130b and intracellular replication of Legionella was assed by a replication assay after 8, 16 and 24 
h. Results are means ± SEM of three independent experiments. *, p < 0.05 compared with untreated control or control siRNA versus treated cells or 
target siRNA.
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hBD-3 elicited a strong antimicrobial effect towards L. 
pneumophila
To study the susceptibility of L. pneumophila to hBD-3,
we incubated the wild type 130b in suspension with
increasing concentrations of recombinant hBD-3 and a
cfu assay was performed. As control for inhibition of rep-
lication we used the antibiotic erythromycin [26]. hBD-3
efficiently inhibited replication of this strain of Legionella
in all used concentrations (figure 5A). Next we elucidated
if hBD-3 has an antimicrobial effect towards intracellular
Legionella growth. Therefore we infected A549 cells with
L. pneumophila for a replication assay. Treatment with
hBD-3 reduced the replication of the intracellular bacte-
ria (figure 5B). Finally, the role of endogenous hBD-3 for
intracellular replication of Legionella was tested in A549
cells transfected with hBD-3-specific siRNA or control
siRNA. Knockdown of hBD-3 was confirmed by ELISA
and RT-PCR (data not shown). The intracellular replica-
tion of L. pneumophila 130b was enhanced in cells trans-
fected with specific hBD-3 siRNA compared to cells
transfected with control siRNA (figure 5C), suggesting
the importance of this peptide in Legionella-induced
innate immune response.
Discussion
In the study presented, we demonstrate that L. pneumo-
phila-  induced hBD-3 expression was dependent on
TLR2, TLR5 and TLR9 in human alveolar epithelial cells.
The activation of JNK-pathway was identified to play a
key role for L. pneumophila- triggered hBD-3 release.
Furthermore, detailed analysis of signal transduction
pathways provides evidence that activation of AP-1 sub-
unit c-Jun but not NF-κB plays a key role in L. pneumo-
phila- mediated hBD-3 release (figure 6). We
demonstrated also that hBD-3 elicited an antimicrobial
effect towards L. pneumophila.  W e  a l s o  s h o w e d  t h a t
recombinant hBD-3 decreased replication of Legionella
more efficient in lower concentrations than the antibiotic
erythromycin used in treatment of Legionnaires' disease
[26]. The mechanism by which defensins kill or inactivate
bacteria is not precisely understood but is generally
thought to be related to a perforation of the peripheral
microbial membrane [12]. A recently published study
showed a co-localisation of endogenous hBD-2 with the
bacterial cell wall of extra- and intracellular replicating
Mycobacterium tuberculosis in A549 cells [27]. For hBD-3
a similar antimicrobial mechanism can be assumed since
a keratinocyte cell line engineered to overexpress hBD-3
demonstrated significant antimicrobial activity against
Staphylococcus aureus [28]. On the other hand, hBD-3
can activate the NF-κB pathway via a TLR-triggered
mechanisms [29]). This may induce secondary effector
molecules which may reduce intracellular replication of
Legionella. Since we observed in our study an antimicro-
bial effect within four hours, we presume that hBD-3 kills
L. pneumophila via direct perforation of the bacterial
membrane.
The expression of hBD-3 in respiratory cells, especially
in infections of the lung, is not well understood and was
so far rather investigated in studies of oral infections as
well as in epithelium of skin and intestine
[12,16,17,30,31]. Our data showed that L. pneumophila
infection of pulmonary epithelium and alveolar mac-
rophages led to increased mRNA levels of hBD-3 and a
strong secretion of this peptide. Since different isolates of
L. pneumophila serogroup1 were found to induce a com-
parable release of hBD-3, it is likely that hBD-3 produc-
tion is a common response of lung epithelial cells to L.
pneumophila infection. This assumption is supported by
a study which showed increased hBD-3 concentrations in
respiratory tract and serum of patients suffering bacterial
pneumonia [14]. In this study, hBD-3 exhibited a strong
antibacterial effect on Staphylococcus aureus, Escherichia
coli  and  Pseudomonas aeruginosa [14]. Since we also
demonstrated that hBD-3 has an antimicrobial effect
towards L. pneumophila and this peptide do orchestrate
the recruitment of alveolar macrophages to the site of
infection [32], we assume that this defensin might be
important for immune response in infectious diseases of
the lung.
Pulmonary epithelial cells may detect L. pneumophila
by TLRs [5-7]. In accordance we demonstrated that rec-
ognition of L. pneumophila by TLR2, TLR5 and TLR9
was essential for the production of hBD-3. In recently
published studies, it was shown that hBD-3 expression
was induced TLR2-dependent in skin epithelial cells
[16,33,34]. To our knowledge, our study showed for the
first time the induction of hBD-3 via activation of TLR5
and TLR9.
In mice pneumonia studies, TLR2, TLR5 and TLR9
were required for effective innate immune responses
against L. pneumophila [5,7,35]. Since we demonstrated
that inhibition of all three TLRs decreases L. pneumo-
phila-induced hBD-3 release, we assume that these
receptors might be essential for antimicrobial innate
immune response in Legionella infections. Interestingly,
hBD-3 liberation was not reduced in infections with type
II or IVB secretion system mutant strains, suggesting that
recognition of bacterial membrane component via TLR2,
recognition of Legionella-flagellin via TLR5 and/or non-
methylated bacterial DNA through TLR9 might be the
major pathways for L. pneumophila induced hBD-3.
A complex signaling network regulates the expression
of inducible hBD-3 [16,17,33]. In L. pneumophila-
infected lung epithelial cells, we noted that the bacteria
induced a JNK-dependent release of hBD-3. This
prompted to the assumption that JNK related transcrip-
tion factor AP-1 is involved in this process. Indeed, weScharf et al. Respiratory Research 2010, 11:93
http://respiratory-research.com/content/11/1/93
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showed that AP-1 subunit c-Jun was recruited to hbd-3
promoter. Our data are in line with previous studies
which demonstrated a strong AP-1 dependency of hBD-3
induction [16,17]. In contrast, a recently reported role of
NF-κB in the regulation of the hBD-3 gene in keratino-
cytes has been published [15]. Since an NF-κB binding
site is also located on hbd-3 promoter, we tested if a bind-
ing of this transcription factor could be observed in L.
pneumophila- infected alveolar epithelial cells and failed
to confirm a binding of NF-κB subunit p65 to this struc-
ture (data not shown). This strengthens our data that
mainly AP-1 was essential for L. pneumophila induced
release of hBD-3 in pulmonary cells.
Functional studies and signal transduction experiments
of this study were performed in A549 cells. Since infec-
tion with L. pneumophila and stimulation with TLR ago-
nists showed comparable expression of hBD-3 in A549
cells and primary SAEC, we assume similarities in regula-
tion of hBD-3 between both cell types. Furthermore, pre-
vious studies by our and other groups demonstrated
analogous behavior of A549 cells and the primary SAEC
in release of cytokines, defensins, prostaglandin E2 as
well as in production of reactive oxygen species after
infection [20,21,24,36,37]. Nevertheless, A549 cells are a
tumor cell line and further studies in vivo are needed to
dissect the signaling pathways mediating L. pneumo-
phila-related defensin release.
Figure 6 Molecular scheme of Legionella pneumophila-induced hBD-3 expression. L. pneumophila activates TLR2, TLR5, and TLR9. Downstream 
signaling leads to the activation of JNK with subsequent recruitment of AP-1 subunit c-jun to the hBD-3 promoter leading to hBD-3 expression.
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In conclusion, we found that L. pneumophila- triggered
hBD-3 release is TLR2, TLR5- and TLR9-dependent
hBD-3 in human pulmonary epithelial cells. Expression
of hBD-3 included activation of the JNK- AP-1 (c-Jun)
pathway, whereas NF-κB was not essential for this pro-
cess in A549 cells. Since control of the immune response
is crucial to assure bacterial clearance and to prevent
excessive tissue damage in pneumonia, the mechanism
described above could be important for the host defense
in Legionnaires' disease.
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